Emmaus life sciences inc new stock is down -100% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.17% of the previous 23 February’s closed higher than January.
Emmaus Life Sciences, Inc. discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!